Lupus Nephritis Clinical Trials in Chicago, Illinois

6 studies are recruiting for lupus nephritis in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. VIBRANT: VIB4920 for Active Lupus Nephritis

   This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago, Department of Medicine: Rheumatology, Chicago, Illinois

   Locations

   17 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT05201469 on ClinicalTrials.gov

2. The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

   The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily …

   Stage

   Phase 2

   Ages

   8 to 20

   Site

   Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

   Locations

   19 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT05538208 on ClinicalTrials.gov

3. A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

   This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopa…

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois

   Locations

   16 in total

   Run by

   CRISPR Therapeutics

   See if you can join NCT06925542 on ClinicalTrials.gov

4. RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Locations

   23 in total

   Run by

   Cabaletta Bio

   See if you can join NCT06121297 on ClinicalTrials.gov

5. A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

   This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Nkarta Investigational Site, Chicago, Illinois

   Locations

   19 in total

   Run by

   Nkarta, Inc.

   See if you can join NCT06557265 on ClinicalTrials.gov

6. Lupus Landmark Study: A Prospective Registry and Biorepository

   The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).

   Stage

   Not phased

   Ages

   18 to 110

   Site

   University of Chicago, Chicago, Illinois

   Locations

   25 in total

   Run by

   Lupus Research Alliance

   See if you can join NCT05934149 on ClinicalTrials.gov